Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: A case series and literature review

Michael Thorpe, Ana Montalvao, Francesca Pierdomenico, Filipa Moita, Antonio Ameida

    Research output: Contribution to journalArticle

    36 Citations (Scopus)

    Abstract

    Chronic myelomonocytic leukemia (CMML) is a clinically heterogeneous disease, with no standard treatment. We present the outcome of ten patients diagnosed with CMML and treated with AZA in our institutions between 2005 and 2010. All patients were transfusion dependent at the time of initiation of therapy. The overall response rate was 60%. Responses were obtained in 2/3 of the patients with proliferative CMML. The median survival from start of therapy was 20 months. AZA treatment was well-tolerated and associated with a significant response rate in all forms of the disease.

    Original languageEnglish
    Pages (from-to)1071-1073
    Number of pages3
    JournalLeukemia Research
    Volume36
    Issue number8
    DOIs
    Publication statusPublished - Aug 2012

    Keywords

    • 5-Azacitidine
    • Chronic myelomonocytic leukemia
    • Hypomethylating agents
    • Myelodysplasia

    Fingerprint Dive into the research topics of 'Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: A case series and literature review'. Together they form a unique fingerprint.

  • Cite this